Replimune's Conditional Comeback: FDA Approval Ends a Bruising Regulatory Chapter

FDA grants accelerated approval to Replimune's TUDRIQEV combo for advanced melanoma, but muted stock reaction and legal probes temper optimism.

The numbers tell a story of cautious optimism rather than euphoria. On August 6, 2026, the FDA granted accelerated approval to Replimune's TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with Nivolumab for advanced melanoma patients who have progressed on anti-PD-1 therapy. The stock's response was muted — a modest gain of 0.72 percent to 10.53 euros on the day, following a 8.56 percent weekly advance. The market had already priced in the outcome.

This approval represents a remarkable turnaround for a company that had been written off by many investors. Replimune had received Complete Response Letters in July 2025 and again in April 2026, with the second rejection triggering a sharp selloff that attracted the attention of securities class action firms. The path to approval only reopened after the FDA's advisory committee voted 10 to 3 in favor of the therapy on July 30, 2026.

A Tumor That Teaches the Immune System

The mechanism behind TUDRIQEV is conceptually elegant. A modified virus infects cancer cells and causes them to rupture, effectively transforming the tumor into its own vaccine. The immune system learns to recognize cancer cells it had previously overlooked — a particularly valuable approach for a patient population with limited options.

The approval rests on data from the IGNYTE study, which demonstrated an overall response rate of 24.2 percent among evaluable patients, with a median duration of response of 14.1 months. Notably, the FDA based its label on a more conservative subgroup of 91 patients rather than the broader cohort of 140 originally discussed. Despite these statistical nuances, the advisory committee's decisive vote signaled that medical need outweighed methodological quibbles.

The Price of Acceleration

The word "accelerated" carries weight. Replimune must now confirm the early results through the ongoing IGNYTE-3 Phase 3 study, which enrolls approximately 400 patients. Results are not expected until late 2027, leaving the approval provisional in the interim. If the confirmatory data disappoint, the regulatory foundation could shift.

Commercial execution presents its own challenges. At roughly 450,000 dollars per treatment cycle, TUDRIQEV demands a functional sales organization and reimbursement infrastructure — a significant transition for a company that has operated primarily as a research enterprise. Analysts estimate peak sales potential ranging from 618 million to just under 971 million dollars, figures that underscore how much of Replimune's 868.27 million euro market capitalization now hinges on this single product.

Legal Clouds and Technical Signals

The approval does not erase the company's legal baggage. Multiple firms, including Pomerantz LLP and Glancy Prongay & Rotter LLP, are pursuing investigations into potential securities fraud related to Replimune's disclosures surrounding the failed applications. These proceedings are expected to continue independently of TUDRIQEV's commercial performance.

Technical indicators suggest a market digesting news rather than chasing it. The relative strength index sits at 60.8, indicating upward momentum without overbought conditions. The consensus price target of 11.27 euros implies roughly 7.8 percent upside from current levels. Yet with annualized 30-day volatility above 335 percent, investors should expect sharp swings in either direction.

Replimune's transformation from clinical-stage developer to commercial entity rarely follows a straight line. The scientific thesis has finally been validated, but the financial verdict remains pending — contingent on IGNYTE-3's results, the resolution of outstanding litigation, and the company's ability to execute a complex product launch. For now, the market is paying attention, but it is not celebrating prematurely.